Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Clinical Trial Grant

Duke Scholars

Principal Investigator Richard Francis Riedel Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Adaptimmune LLC

Start Date

November 22, 2023

End Date

March 14, 2029

Administered By

Duke Cancer Institute

Awarded By

Adaptimmune LLC

Start Date

November 22, 2023

End Date

March 14, 2029